Back to Newsroom

Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL

DOYLESTOWN, Pa., April 27, 2015 /PRNewswire/ — Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced the presentation of preclinical antiviral data for its lead HBV core inhibitor candidate, NVR 3-778, at the 2015 annual meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria.

Click here to read more